Published on
Apr 2, 2025
Human medicines European public assessment report (EPAR): Extavia, interferon beta-1b, Date of authorisation: 20/05/2008,...
Extavia was studied over a two-year period in 338 patients with relapsing remitting MS who were able to walk unaided, where its effectiveness was compared with placebo (a dummy treatment). Extavia was more effective than placebo in reducing the number of …
Source:
European Medicines Agency
-
Label Pending
